INTERNATIONAL PATENT: JANSSEN PHARMACEUTICA NV FILES APPLICATION FOR "COMBINATION THERAPIES WITH HAFNIUM OXIDE NANOPARTICLES AND PD-L1 ANTIBODIES FOR USE IN THE TREATMENT OF NON SMALL CELL LUNG CANCER"

GENEVA, April 13 -- JANSSEN PHARMACEUTICA NV (Turnhoutseweg 302340 Beerse) filed a patent application (PCT/IB2025/059905) for "COMBINATION THERAPIES WITH HAFNIUM OXIDE NANOPARTICLES AND PD-L1 ANTIBODIES FOR USE IN THE TREATMENT OF NON SMALL CELL LUNG CANCER" on Oct 01, 2025. With publication no. WO/2026/074471, the details related to the patent application was published on Apr 09, 2026.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): SZAPARY, Philippe (c/o Johnson & Johnson Enterprise Innovation Inc.One Johnson & Johnson PlazaNew Brunswick, New Jersey 08933), DEVISETTY, Kiran (c/o Johnson & Johnso...